{"summary": "two lead candidates funded by BARDA are nearing consideration for licensure. the Ad26-ZEBOV/MVA-BN-Filo prime-boost vaccine is safe and well tolerated. the vaccine produces sustained immune responses up to one year post vaccination. ZMapp is widely considered to be a component of standard of care. it was part of the response to the march 2016 outbreak that originated in the Nz\u00e9r\u00e9kor\u00e9 prefecture in Guinea [17] and spread to liberia. it was also available for use in the May 2017 outbreak in the Democratic Republic of the Congo. advanced development organization for medical countermeasures is positioned to contribute to larger global initiatives that address emerging and neglected tropical diseases when outbreaks of international concern arise. despite advancement of the aforementioned vaccines and therapeutics against Ebola, gaps remain in our overall preparedness posture against other filoviruses."}